Breaking News
February 21, 2018 - ‘Grey’s Anatomy’ Traumas Lack Realism
February 21, 2018 - Sleep quality improves with help of incontinence drug
February 21, 2018 - Scientists uncover genetic cause behind typhoid’s antibiotic resistance
February 21, 2018 - Study reveals a significant link between heavy alcohol use and dementia
February 21, 2018 - French scientists develop new wearable laser that eradicates skin conditions
February 21, 2018 - People with major depressive disorder have reduced arginine levels, study shows
February 21, 2018 - National Health Spending at $3.5 Trillion in 2017, CMS Says
February 21, 2018 - Substantial inequalities in cesarean births persist in many countries
February 21, 2018 - Early childhood immune signature predicts risk of developing asthma later on
February 21, 2018 - Stanford researchers explore how gut bacteria respond to common changes in habitat
February 21, 2018 - Household Products May Pollute the Air as Much as Your Car Does: Study
February 21, 2018 - Combo Bests Targeted Agent in mRCC
February 21, 2018 - Researchers discover brain pathway that dissociates opioid addiction from analgesia
February 21, 2018 - Scientists uncover how newly discovered gene helps grow blood vessels
February 21, 2018 - Brain’s quality control process holds clues to obesity’s roots
February 21, 2018 - Researchers to study whether menstrual cups can help prevent vaginal infections
February 21, 2018 - MS patients who feel stigmatized more likely to suffer from depression
February 21, 2018 - Vitamin D supplementation during pregnancy could protect against childhood obesity
February 21, 2018 - Lower-Quality Medical Tx Might Have Skewed Key PCI vs CABG Trials
February 21, 2018 - Love and fear are visible across the brain instead of being restricted to any brain region
February 21, 2018 - Researchers discover potential new antimalarial treatment targets
February 21, 2018 - Adults with congenital heart disease have increased risk for dementia, study finds
February 21, 2018 - Clinical trial studying type 1 diabetes reaches full enrollment
February 21, 2018 - Father’s stress affects the brain development of offspring, mice study shows
February 21, 2018 - ESRD Death Declines in Vasculitis Patients
February 21, 2018 - Taking ibuprofen for long periods found to alter human testicular physiology
February 21, 2018 - Google AI device could predict a person’s risk of a heart attack
February 20, 2018 - FDA Approves Domestic Source for Tc-99m Isotopes
February 20, 2018 - Sanofi rejects refund demand faces Philippine suit over dengue vaccine (Update)
February 20, 2018 - Researchers discover that activation of specific enzyme may help suppress tumor metastasis
February 20, 2018 - Blood or marrow transplantation survivors have higher risk of cognitive impairment
February 20, 2018 - Booze Beats Pot at Being Unhealthy: Oregon Poll
February 20, 2018 - Morning Break: ’20 Years Late’; Drugs in the Dirt; Catching Flu in the Dorm
February 20, 2018 - Another piece to the puzzle in naked mole rats’ long, cancer-free life
February 20, 2018 - Scientists identify four viruses that can produce insulin-like hormones
February 20, 2018 - New e-Health solution developed to prevent cardiovascular disease, dementia in senior citizens
February 20, 2018 - New genetic risk score could help guide screening decisions for prostate cancer
February 20, 2018 - Study finds higher risk of stroke among blacks with atrial fibrillation than whites
February 20, 2018 - Physical activity could be used as strategy for diabetes prevention
February 20, 2018 - Researchers develop sensing method for early detection of cancer and diabetes
February 20, 2018 - New wearable electronics could be game-changer for stroke rehabilitation
February 20, 2018 - Immune history influences person’s response to flu vaccine
February 20, 2018 - Research findings could help develop new drugs to prevent, treat dry eye disease
February 20, 2018 - Serenity Now! Learn to Have Patience with Patients
February 20, 2018 - Computer simulation addresses the problem of blood clotting
February 20, 2018 - Women with type 1 diabetes not protected against coronary artery disease
February 20, 2018 - Persistent bloating can be a sign of ovarian cancer, warns charity
February 20, 2018 - Trump administration proposes rule to loosen curbs on short-term health plans
February 20, 2018 - Key protein involved in epigenetic regulation of gene expression guides skin cell renewal
February 20, 2018 - Heart attack symptoms often missed in women
February 20, 2018 - Diagnosis of celiac disease takes 3.5 years for patients who do not report GI symptoms
February 20, 2018 - Study reveals functional dynamics of ion channels
February 20, 2018 - Study explores link between mortality risk and combustible tobacco use
February 20, 2018 - ‘She Trusted Me, and I’d Turned Her Away’
February 20, 2018 - AbbVie and Voyager Therapeutics collaborate to develop new treatments for tauopathies
February 20, 2018 - Fast food makes the immune system more aggressive in the long term
February 20, 2018 - Therapeutic target for glaucoma could have treatment ramifications for Alzheimer’s and Parkinson’s
February 20, 2018 - Overcoming Negative Reviews | Medpage Today
February 20, 2018 - MyD88—villain of allergies and asthma
February 20, 2018 - Food scientists develop rapid screening technique to detect pesticide residue in vegetables
February 20, 2018 - Lab-grown cerebellar cells may help explain how ASD develops at molecular level
February 20, 2018 - Scientists explore connection between bad sleep habits and stiff blood vessels
February 20, 2018 - New Treatment Apalutamide (Erleada) Approved for Prostate Cancer That Resists Hormone Therapy
February 20, 2018 - Do You Really Need My Signature on That?
February 20, 2018 - HIV-1 genetic diversity is higher in vaginal tract than in blood during early infection
February 20, 2018 - Diabetes does not increase work-loss years due to early retirement
February 20, 2018 - Researchers aim to find out how PTSD affects decisions of police
February 20, 2018 - UH Cleveland Medical Center explores novel treatments for uterine fibroids
February 20, 2018 - Flu Vax Efficacy 25% Against Predominant H3N2 Strain So Far
February 20, 2018 - HIV screening most optimal at 25 years of age if no risk factors
February 20, 2018 - Loyola Medicine primary care physician offers advice to minimize risk of flu
February 20, 2018 - Safe sleep recommendations for parents that may help reduce child’s risk of SUID
February 20, 2018 - Why Do So Few Docs Have Buprenorphine Waivers?
February 20, 2018 - Low levels of alcohol good for the brain
February 20, 2018 - Experimental treatment improves invisible symptoms of a man with spinal cord injury
February 20, 2018 - Myriad’s EndoPredict offers better prediction of breast cancer recurrence, analysis shows
February 20, 2018 - Researchers identify fifteen genes that determine our facial features
February 20, 2018 - Morning Break: New Health IT Player; Luxturna No Bargain; Nuclear Freakout
February 20, 2018 - How does it compare? Hospice care at home, at assisted living facility, at nursing home
February 19, 2018 - Scientists develop water-soluble warped nanographene for bioimaging
Trastuzumab No Benefit In Low-HER2 Breast Cancer

Trastuzumab No Benefit In Low-HER2 Breast Cancer

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
  • Treating high-risk breast cancer patients who tested low for HER2-receptor status with trastuzumab (Herceptin) provided no benefit in disease-free survival over women who are treated only with chemotherapy.
  • There were no statistically significant differences when looking at stratification by level of HER2-low status; by the number of positive lymph nodes; by hormone receptor status; or by type of chemotherapy.

SAN ANTONIO – Treating high-risk breast cancer patients who tested low for HER2-receptor status with trastuzumab (Herceptin) provided no benefit in disease-free survival over women who are treated only with chemotherapy, researchers reported here.

The 5-year overall invasive disease-free survival was 89.2% of women treated with chemotherapy alone compared with disease free survival of 89.6% in the women who were given chemotherapy and trastuzumab (P=0.90), reported Louis Fehrenbacher, MD, of Kaiser Permanente Northern California in Vallejo.

“We observed an overall survival of 95% in both arms of the trial,” he told MedPage Today at the 2017 San Antonio Breast Cancer Symposium.

Invasive disease events occurred in 134 women receiving just chemotherapy and 130 women getting chemotherapy plus trastuzumab during the 5 years of the study, Fehrenbacher reported at an SABCS press conference.

The trial was prompted by a finding in the 2005 National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 study. Its main finding was an advantage for trastuzumab in women with HER2-receptor overexpression, but it also found a possible advantage in a small subset of women who were apparently misidentified as having overexpression but actually had low HER2 levels. Fehrenbacher and colleagues wanted to confirm whether this was real or some sort of fluke.

Apparently it was the latter.

“We usually don’t present studies with negative findings but these results are very important because we have many patients who are 1+ and 2+ and we have been wondering if we should be giving them a fairly expensive drug with side effect for a full year,” said Virginia Kaklamani, MD, of UT Health at San Antonio.

Why the current study – designated as NSABP B-47 – did not confirm the earlier result is not readily explained, Fehrenbacher said. He speculated that, in the earlier study, the HER2-low cases might actually have been HER2-positive. The findings in the original trial showed a trend toward benefit in the small group of patients, but those findings did not reach statistical significance.

To pursue the possible use of HER2-targeted agents in this expanded community of HER2-low breast cancer, Fehrenbacher and colleagues enrolled 3,270 women who were identified as having HER2-low breast cancer by immunohistochemistry (1+, 2+) — a level that would not normally be treated with trastuzumab.

They received chemotherapy at the choice of their provider, either doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 in four cycles every 3 weeks followed by 12 weeks of once-weekly paclitaxel; or docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 every 3 weeks for six cycles. The chemotherapy alone was randomly provided to 1,603 women; the chemotherapy plus trastuzumab was given to 1,599 women. There were 63 patients (1.9%) lost to follow-up.

“This will probably reduce the amount of trastuzumab being used, although it shouldn’t,” Fehrenbacher said. “There were probably a few cases in which the women had low or near HER2 levels but not quite the 3+ required. I think that the number of these patients being treated with trastuzumab is pretty low at the moment, but that number should go to zero. There was no benefit and there was toxicity, it is time consuming and it is expensive.”

He said that there were no statistically significant differences when looking at stratification by level of HER2-low status; by the number of positive lymph nodes; by hormone receptor status; or by type of chemotherapy. “There were no trends for efficacy observed,” he said.

Fehrenbacher said that the high survival was somewhat of a surprise: “These patients did extremely well. If you look at studies of outcomes over 30 years you see that there is an incremental improvement in the same stages of cancer decade after decade. Whether that is due to more lower stage diagnosis, less risk within the same stage, or maybe the treatment is better, the organization is better in providing care … it is hard to know why but it is very clear that outcomes in each stage are improving.”

Fehrenbacher disclosed relevant relationships with Genentech/Roche, CellDex, Abbvie, Macrogenitcs, Cascadian and Pfizer.

Kaklamani disclosed relevant relationships with Novartis and Pfizer.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner


Tagged with:

About author

Related Articles